Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: Therapeutic applications and considerations-Reference-Cited by-同舟云学术

Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: Therapeutic applications and considerations

Published:2003-04 Issue:2 Volume:30 Page:248-252
ISSN:0093-7754
Container-title:Seminars in Oncology
language:en
Short-container-title:Seminars in Oncology

Author:

Treon Steven P.,Kelliher Abigail,Keele Beverly,Frankel Stanley,Emmanouilides Christos,Kimby Eva,Schlossman Robert,Mitsiades Nicholas,Mitsiades Constantine,Preffer Frederic,Anderson Kenneth C.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference21 articles.

1. Waldenstrom's macroglobulinemia: Clinical features, complications, and management;Dimopoulos;J Clin Oncol,2000

2. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program;McLaughlin;J Clin Oncol,1998

3. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia;Osterborg;J Clin Oncol,1997

4. Immunotherapy of non-Hodgkin's lymphoma with epratuzumab, an anti-CD22 monoclonal antibody and HU1D10 (apolizumab);Leonard;Semin Oncol,2002

5. A phase II study of Remitogen (HU1D10), a humanized monoclonal antibody in patients with relapsed or refractory follicular, small lymphocytic, or marginal zone/MALT B-cell lymphoma;Link;Blood,2001

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Waldenstrom Macroglobulinemia;Comprehensive Hematology and Stem Cell Research;2024

2. Waldenström’s Macroglobulinemia;Hematologic Malignancies;2018

3. Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma;Hematology;2018

4. Waldenstrom’s Macroglobulinemia;Neoplastic Diseases of the Blood;2017-09-09

5. Current treatment options and investigational drugs for Waldenstrom’s Macroglobulinemia;Expert Opinion on Investigational Drugs;2017-01-03